QoL · men with lower urinary tract symptoms secondary to benign prostatic obstruction
1 finding from 1 review
Adverse events · men with lower urinary tract symptoms secondary to benign prostatic obstruction
Combination therapy probably leads to higher adverse events compared with placebo (moderate certainty).
1 finding from 1 review
AUR · men with lower urinary tract symptoms secondary to benign prostatic obstruction
It is very uncertain whether combination therapy changes AUR compared with placebo (very low certainty).
1 finding from 1 review
Surgical intervention – not reported · men with lower urinary tract symptoms secondary to benign prostatic obstruction
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Urologic symptom scores · men with lower urinary tract symptoms secondary to benign prostatic obstruction
1 finding from 1 review
QoL · men with lower urinary tract symptoms secondary to benign prostatic obstruction
1 finding from 1 review
Adverse events · men with lower urinary tract symptoms secondary to benign prostatic obstruction
Combination therapy showed no clear difference in adverse events compared with alpha‐blockers (low certainty).
1 finding from 1 review
AUR · men with lower urinary tract symptoms secondary to benign prostatic obstruction
Combination therapy showed no clear difference in AUR compared with alpha‐blockers (low certainty).
1 finding from 1 review
Death (all causes)
Early taxane‐based chemotherapy and androgen deprivation therapy (ADT) probably leads to lower time to death due to any cause (absolute effect size estimates based… compared with ADT only (moderate certainty).
1 finding from 1 review
Adverse events grade 3 to 5 Range of
Early taxane‐based chemotherapy and androgen deprivation therapy (ADT) may leads to higher grade III to V adverse events compared with ADT only (low certainty).
1 finding from 1 review
Prostate cancer‐specific death5
Early taxane‐based chemotherapy and androgen deprivation therapy (ADT) probably leads to lower prostate cancer‐specific death5 compared with ADT only (moderate certainty).
1 finding from 1 review
Time to progression
Early taxane‐based chemotherapy and androgen deprivation therapy (ADT) probably leads to lower time to progression (absolute effect size estimates based on… compared with ADT only (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events
Early taxane‐based chemotherapy and androgen deprivation therapy (ADT) may leads to higher discontinuation due to adverse events compared with ADT only (low certainty).
1 finding from 1 review
All adverse events
Early taxane‐based chemotherapy and androgen deprivation therapy (ADT) may leads to higher all adverse events compared with ADT only (low certainty).
1 finding from 1 review
Quality of life at 12 months (
1 finding from 1 review
Outcomes ( · men with Peyronie's disease (diagnosis of disease: varying, penile curvature: at least 30 degrees)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Patient‐reported ability to have intercourse · men with Peyronie's disease (diagnosis of disease: varying, penile curvature: at least 30 degrees)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life · men with Peyronie's disease (diagnosis of disease: varying, penile curvature: at least 30 degrees)
1 finding from 1 review
Treatment‐related adverse effects · men with Peyronie's disease (diagnosis of disease: varying, penile curvature: at least 30 degrees)
1 finding from 1 review
Degree of penile curvature · men with Peyronie's disease (diagnosis of disease: varying, penile curvature: at least 30 degrees)
1 finding from 1 review